Aberrant Processing of Plasma Vitronectin and High-Molecular-Weight Kininogen Precedes the Onset of Preeclampsia

Abstract

To date, there is no reliable test to identify women in early pregnancy at risk of developing preeclampsia. Difference gel electrophoresis (DIGE) identified the plasma proteins vitronectin (VN) and high-molecular-weight kininogen (HK) in association with preeclampsia. In a longitudinal proteomics study, the plasma of preeclamptic patients (n = 6) was compared to healthy control participants (n = 6) before the onset of preeclampsia (week 20) and at the time of presentation with clinical disease (weeks 33-36). The 75-kd single-chain VN molecule increased 1.6- to 1.9-fold in preeclampsia, whereas the 65-kd moiety of the 2-chain VN molecule decreased 1.5- to 1.7-fold compared to healthy controls (P < .05). Immunoblots revealed differences in proteolytic processing of VN and/or HK in women who develop preeclampsia or preeclampsia further complicated by small-for-gestational-age. Vitronectin and HK may prove to be useful as early markers of fibrinolytic activity and neutrophil activation, which are known to be associated with preeclampsia.

Keywords

Preeclampsia small-for-gestational-age difference in gel electrophoresis plasma vitronectin high molecular weight kininogen.

Get full access to this article

View all access options for this article.

References

Sibai B. , Dekker G. , Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-799.

Pijnenborg R. , Anthony J. , Davey DA , et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol . 1991;98(7):648-655.

Redman CW , Sargent IL Latest advances in understanding preeclampsia. Science . 2005;308(5728):1592-1594.

Bellamy L. , Casas JP , Hingorani AD , Williams DJ Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007; 335(7627):974.

Heitner JC , Koy C. , Kreutzer M. , Gerber B. , Reimer T. , Glocker MO Differentiation of HELLP patients from healthy pregnant women by proteome analysis-on the way towards a clinical marker set. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;840(1):10-19.

Watanabe H. , Hamada H. , Yamada N. , et al. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics. 2004;4(2):537-543.

Brown MA , Hague WM , Higgins J. , et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol. 2000;40(2):139-155.

Gardosi J. , Mongelli M. , Wilcox M. , Chang A. An adjustable fetal weight standard. Ultrasound Obstet Gynecol . 1995;6(3):168-174.

Benjamini Y. , Hochberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Stat. 2000;25(1):60-83.

10.

Hardt M. , Thomas LR , Dixon SE , et al. Toward defining the human parotid gland salivary proteome and peptidome: identification and characterization using 2D SDS-PAGE, ultrafiltration, HPLC, and mass spectrometry. Biochemistry. 2005;44(8):2885-2899.

11.

Campostrini N. , Areces LB , Rappsilber J. , et al. Spot overlapping in two-dimensional maps: a serious problem ignored for much too long. Proteomics . 2005;5(9):2385-2395.

12.

Colman RW Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des. 2006;12(21):2599-2607.

13.

Colman RW , Jameson BA , Lin Y. , Johnson D. , Mousa SA Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000;95(2):543-550.

14.

Schvartz I. , Seger D. , Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999;31(5):539-544.

15.

Chauhan AK , Moore TL. Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC). Clin Exp Immunol. 2006;145(3):398-406.

16.

Preissner KT , Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thrombosis Res. 1998 ;89(1):1-21.

17.

Seiffert D. , Schleef RR Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. Blood. 1996;88(2):552-560.

18.

Schroeck F. , Arroyo de Prada N. , Sperl S. , Schmitt M. , Viktor M. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn. Biol Chem. 2002;383(7-8):1143-1149.

19.

Conlan MG , Tomasini BR , Schultz RL , Mosher DF Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation. Blood. 1988;72(1):185-190.

20.

Tollefsen DM , Weigel CJ , Kabeer MH The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at arginine 379. J Biol Chem. 1990 ;265(17):9778-9781.

21.

Zhou Y. , Fisher SJ , Janatpour M. , et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest . 1997;99(9):2139-2151.

22.

Xu P. , Wang Y. , Piao Y. , et al. Effects of matrix proteins on the expression of matrix metalloproteinase-2, -9, and -14 and tissue inhibitors of metalloproteinases in human cytotrophoblast cells during the first trimester. Biol Reprod. 2001;65(1): 240-246.

23.

Pijnenborg R. , Luyten C. , Vercruysse L. , Van Assche FA Attachment and differentiation in vitro of trophoblast from normal and preeclamptic human placentas. Am J Obstet Gynecol. 1996;175(1):30-36.

24.

Stefansson S. , McMahon GA , Petitclerc E. , Lawrence DA Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling . Curr Pharm Des . 2003;9(19):1545-1564.

25.

Konstantinides S. , Schäfer K. , Loskutoff DJ. Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain. Arterioscler Thromb Vasc Biol. 2002;22(12):1943-1945.

26.

Stark JM Disequilibrium in control of proteolysis as a cause of pre-eclampsia . Lancet. 1978;1(8061):417-419.

27.

Folkman J. Tumor angiogenesis. Adv Cancer Res. 1974; 19(0):331-358.

28.

Wu Y. , Rizzo V. , Liu Y. , Sainz IM , Schmuckler NG , Colman RW Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27(9):1968-1975.

29.

Kleniewski J. , Blankenship DT , Cardin AD , Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin . J Lab Clin Med. 1992;120(1):129-139.

30.

Kleniewski J. , Donaldson V. Granulocyte elastase cleaves human high molecular weight kininogen and destroys its clot-promoting activity. J Exp Med. 1988;167(6): 1895-1907.

31.

Kozik A. , Moore RB , Potempa J. , Imamura T. , Rapala-Kozik M. , Travis J. A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J Biol Chem. 1998;273(50):33224-33229.

32.

Gupta AK , Gebhardt S. , Hillermann R. , Holzgreve W. , Hahn S. Analysis of plasma elastase levels in early and late onset preeclampsia . Arch Gynecol Obstet. 2006;273(4):239-242.